LEXICON PHARMACEUTICALS, INC. Operating Expenses
LEXICON PHARMACEUTICALS, INC. (LXRX) reported Operating Expenses of -$31.17 million for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-04.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2023-05-04
- LEXICON PHARMACEUTICALS, INC. operating expenses for the quarter ending 2023-03-31 was -$31.17M, a 233.09% decline year-over-year.
- LEXICON PHARMACEUTICALS, INC. operating expenses for the quarter ending 2022-12-31 was $30.31M, a 19.58% increase year-over-year.
- LEXICON PHARMACEUTICALS, INC. operating expenses for the quarter ending 2022-09-30 was -$23.13M, a 200.65% decline year-over-year.
- LEXICON PHARMACEUTICALS, INC. operating expenses for the quarter ending 2022-06-30 was -$24.04M, a 232.15% decline year-over-year.
- LEXICON PHARMACEUTICALS, INC. operating expenses for fiscal 2022 was $100.90M, a 15.46% increase from fiscal 2021.
- LEXICON PHARMACEUTICALS, INC. operating expenses for fiscal 2021 was $87.39M, a 57.24% decline from fiscal 2020.
- LEXICON PHARMACEUTICALS, INC. operating expenses for fiscal 2020 was $204.38M, a 13.15% increase from fiscal 2019.
- LEXICON PHARMACEUTICALS, INC. operating expenses for fiscal 2019 was $180.63M, a 8.49% increase from fiscal 2018.
| Period end | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 6 month | Operating Expenses 6 month as first filed | Operating Expenses 9 month | Operating Expenses 9 month as first filed | Operating Expenses 12 month | Operating Expenses 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2023-03-31 | -$31.17M 10-Q · filed 2023-05-04 | -$860.00K derived: sum of 2 quarters · filed 2023-05-04 | -$23.99M derived: sum of 3 quarters · filed 2023-05-04 | -$48.04M derived: sum of 4 quarters · filed 2023-05-04 | ||||
| 2022-12-31 | $30.31M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03 | $7.17M derived: sum of 2 quarters · filed 2023-03-03 | -$16.87M derived: sum of 3 quarters · filed 2023-03-03 | $100.90M 10-K · filed 2023-03-03 | ||||
| 2022-09-30 | -$23.13M 10-Q · filed 2022-11-09 | -$47.18M derived: sum of 2 quarters · filed 2022-11-09 | $70.59M 10-Q · filed 2022-11-09 | $1.58M derived: sum of 4 quarters · filed 2023-05-04 | ||||
| 2022-06-30 | -$24.04M 10-Q · filed 2022-08-03 | $47.46M 10-Q · filed 2022-08-03 | $24.72M derived: sum of 3 quarters · filed 2023-05-04 | $47.70M derived: sum of 4 quarters · filed 2023-05-04 | ||||
| 2022-03-31 | $23.42M 10-Q · filed 2023-05-04 | $48.76M derived: sum of 2 quarters · filed 2023-05-04 | $71.75M derived: sum of 3 quarters · filed 2023-05-04 | $89.94M derived: sum of 4 quarters · filed 2023-05-04 | ||||
| 2021-12-31 | $25.34M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03 | $48.33M derived: sum of 2 quarters · filed 2023-03-03 | $66.52M derived: sum of 3 quarters · filed 2023-03-03 | $87.39M 10-K · filed 2023-03-03 | ||||
| 2021-09-30 | $22.98M 10-Q · filed 2022-11-09 | $41.18M derived: sum of 2 quarters · filed 2022-11-09 | $62.04M 10-Q · filed 2022-11-09 | $69.47M derived: sum of 4 quarters · filed 2023-03-03 | ||||
| 2021-06-30 | $18.19M 10-Q · filed 2022-08-03 | $39.06M 10-Q · filed 2022-08-03 | $46.48M derived: sum of 3 quarters · filed 2023-03-03 | $99.26M derived: sum of 4 quarters · filed 2023-03-03 | ||||
| 2021-03-31 | $20.87M 10-Q · filed 2022-05-05 | $28.29M derived: sum of 2 quarters · filed 2023-03-03 | $81.07M derived: sum of 3 quarters · filed 2023-03-03 | $154.81M derived: sum of 4 quarters · filed 2023-03-03 | ||||
| 2020-12-31 | $7.42M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03 | $60.20M derived: sum of 2 quarters · filed 2023-03-03 | $133.94M derived: sum of 3 quarters · filed 2023-03-03 | $204.38M 10-K · filed 2023-03-03 | ||||
| 2020-09-30 | $52.78M 10-Q · filed 2021-11-09 | $126.52M derived: sum of 2 quarters · filed 2021-11-09 | $196.96M 10-Q · filed 2021-11-09 | $252.90M derived: sum of 4 quarters · filed 2022-03-10 | ||||
| 2020-06-30 | $73.74M 10-Q · filed 2021-08-06 | $144.18M 10-Q · filed 2021-08-06 | $200.12M derived: sum of 3 quarters · filed 2022-03-10 | $269.89M derived: sum of 4 quarters · filed 2022-03-10 | ||||
| 2020-03-31 | $70.44M 10-Q · filed 2021-05-06 | $126.38M derived: sum of 2 quarters · filed 2022-03-10 | $196.15M derived: sum of 3 quarters · filed 2022-03-10 | $224.38M derived: sum of 4 quarters · filed 2022-03-10 | ||||
| 2019-12-31 | $55.94M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $125.72M derived: sum of 2 quarters · filed 2022-03-10 | $153.94M derived: sum of 3 quarters · filed 2022-03-10 | $180.63M 10-K · filed 2022-03-10 | ||||
| 2019-09-30 | $69.77M 10-Q · filed 2020-10-30 | $98.00M derived: sum of 2 quarters · filed 2020-10-30 | $124.68M 10-Q · filed 2020-10-30 | $154.12M derived: sum of 4 quarters · filed 2021-03-12 | ||||
| 2019-06-30 | $28.23M 10-Q · filed 2020-07-29 | $54.91M 10-Q · filed 2020-07-29 | $84.35M derived: sum of 3 quarters · filed 2021-03-12 | $114.24M derived: sum of 4 quarters · filed 2021-03-12 | ||||
| 2019-03-31 | $26.68M 10-Q · filed 2020-04-27 | $56.12M derived: sum of 2 quarters · filed 2021-03-12 | $86.02M derived: sum of 3 quarters · filed 2021-03-12 | $130.09M derived: sum of 4 quarters · filed 2021-03-12 | ||||
| 2018-12-31 | $29.44M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | $59.33M derived: sum of 2 quarters · filed 2021-03-12 | $103.40M derived: sum of 3 quarters · filed 2021-03-12 | $166.49M 10-K · filed 2021-03-12 | ||||
| 2018-09-30 | $29.89M 10-Q · filed 2019-11-07 | $29.90M 10-Q · filed 2018-11-01 | $73.96M derived: sum of 2 quarters · filed 2019-11-07 | $137.05M 10-Q · filed 2019-11-07 | $137.25M 10-Q · filed 2018-11-01 | $196.18M derived: sum of 4 quarters · filed 2020-03-12 | ||
| 2018-06-30 | $44.07M 10-Q · filed 2019-08-01 | $44.18M 10-Q · filed 2018-07-30 | $107.16M 10-Q · filed 2019-08-01 | $107.36M 10-Q · filed 2018-07-30 | $166.28M derived: sum of 3 quarters · filed 2020-03-12 | $222.75M derived: sum of 4 quarters · filed 2020-03-12 | ||
| 2018-03-31 | $63.09M 10-Q · filed 2019-05-01 | $63.17M 10-Q · filed 2018-05-03 | $122.22M derived: sum of 2 quarters · filed 2020-03-12 | $178.68M derived: sum of 3 quarters · filed 2020-03-12 | $224.62M derived: sum of 4 quarters · filed 2020-03-12 | |||
| 2017-12-31 | $59.13M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $115.59M derived: sum of 2 quarters · filed 2020-03-12 | $161.53M derived: sum of 3 quarters · filed 2020-03-12 | $222.31M 10-K · filed 2020-03-12 | $227.02M 10-K · filed 2018-03-01 | |||
| 2017-09-30 | $56.46M 10-Q · filed 2018-11-01 | $102.41M derived: sum of 2 quarters · filed 2018-11-01 | $163.18M 10-Q · filed 2018-11-01 | $203.49M derived: sum of 4 quarters · filed 2019-03-15 | ||||
| 2017-06-30 | $45.95M 10-Q · filed 2018-07-30 | $106.72M 10-Q · filed 2018-07-30 | $147.03M derived: sum of 3 quarters · filed 2019-03-15 | $209.68M derived: sum of 4 quarters · filed 2019-03-15 | ||||
| 2017-03-31 | $60.78M 10-Q · filed 2018-05-03 | $101.08M derived: sum of 2 quarters · filed 2019-03-15 | $163.73M derived: sum of 3 quarters · filed 2019-03-15 | $220.84M derived: sum of 4 quarters · filed 2019-03-15 | ||||
| 2016-12-31 | $40.30M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-15 | $102.95M derived: sum of 2 quarters · filed 2019-03-15 | $160.06M derived: sum of 3 quarters · filed 2019-03-15 | $206.43M 10-K · filed 2019-03-15 | $220.49M 10-K · filed 2017-03-06 | |||
| 2016-09-30 | $62.65M 10-Q · filed 2017-11-08 | $119.76M derived: sum of 2 quarters · filed 2017-11-08 | $166.13M 10-Q · filed 2017-11-08 | $205.04M derived: sum of 4 quarters · filed 2018-03-01 | ||||
| 2016-06-30 | $57.11M 10-Q · filed 2017-08-01 | $103.47M 10-Q · filed 2017-08-01 | $142.40M derived: sum of 3 quarters · filed 2018-03-01 | $176.64M derived: sum of 4 quarters · filed 2018-03-01 | ||||
| 2016-03-31 | $46.37M 10-Q · filed 2017-05-04 | $85.28M derived: sum of 2 quarters · filed 2018-03-01 | $119.53M derived: sum of 3 quarters · filed 2018-03-01 | $146.59M derived: sum of 4 quarters · filed 2018-03-01 | ||||
| 2015-12-31 | $38.92M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $73.16M derived: sum of 2 quarters · filed 2018-03-01 | $100.23M derived: sum of 3 quarters · filed 2018-03-01 | $128.55M 10-K · filed 2018-03-01 | ||||
| 2015-09-30 | $34.24M 10-Q · filed 2016-11-07 | $61.31M derived: sum of 2 quarters · filed 2016-11-07 | $89.63M 10-Q · filed 2016-11-07 | $114.56M derived: sum of 4 quarters · filed 2017-03-06 | ||||
| 2015-06-30 | $27.06M 10-Q · filed 2016-08-04 | $55.38M 10-Q · filed 2016-08-04 | $80.31M derived: sum of 3 quarters · filed 2017-03-06 | $121.07M derived: sum of 4 quarters · filed 2017-03-06 | ||||
| 2015-03-31 | $28.32M 10-Q · filed 2016-05-05 | $53.25M derived: sum of 2 quarters · filed 2017-03-06 | $94.00M derived: sum of 3 quarters · filed 2017-03-06 | $120.79M derived: sum of 4 quarters · filed 2017-03-06 | ||||
| 2014-12-31 | $24.93M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-06 | $65.68M derived: sum of 2 quarters · filed 2017-03-06 | $92.47M derived: sum of 3 quarters · filed 2017-03-06 | $123.22M 10-K · filed 2017-03-06 | ||||
| 2014-09-30 | $40.76M 10-Q · filed 2015-11-09 | $67.54M derived: sum of 2 quarters · filed 2015-11-09 | $98.29M 10-Q · filed 2015-11-09 | $116.68M derived: sum of 4 quarters · filed 2016-03-11 | ||||
| 2014-06-30 | $26.79M 10-Q · filed 2015-08-07 | $57.54M 10-Q · filed 2015-08-07 | $75.92M derived: sum of 3 quarters · filed 2016-03-11 | $107.38M derived: sum of 4 quarters · filed 2016-03-11 | ||||
| 2014-03-31 | $30.75M 10-Q · filed 2015-05-05 | $49.13M derived: sum of 2 quarters · filed 2016-03-11 | $80.59M derived: sum of 3 quarters · filed 2016-03-11 | $109.43M derived: sum of 4 quarters · filed 2016-03-11 | ||||
| 2013-12-31 | $18.39M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-11 | $49.84M derived: sum of 2 quarters · filed 2016-03-11 | $78.68M derived: sum of 3 quarters · filed 2016-03-11 | $104.59M 10-K · filed 2016-03-11 | ||||
| 2013-09-30 | $31.45M 10-Q · filed 2014-11-06 | $60.29M derived: sum of 2 quarters · filed 2014-11-06 | $86.21M 10-Q · filed 2014-11-06 | $110.92M derived: sum of 4 quarters · filed 2015-03-12 | ||||
| 2013-06-30 | $28.84M 10-Q · filed 2014-08-07 | $54.75M 10-Q · filed 2014-08-07 | $79.46M derived: sum of 3 quarters · filed 2015-03-12 | $108.89M derived: sum of 4 quarters · filed 2015-03-12 | ||||
| 2013-03-31 | $25.91M 10-Q · filed 2014-05-08 | $50.63M derived: sum of 2 quarters · filed 2015-03-12 | $80.06M derived: sum of 3 quarters · filed 2015-03-12 | $105.74M derived: sum of 4 quarters · filed 2015-03-12 | ||||
| 2012-12-31 | $24.71M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | $54.14M derived: sum of 2 quarters · filed 2015-03-12 | $79.82M derived: sum of 3 quarters · filed 2015-03-12 | $109.50M 10-K · filed 2015-03-12 | ||||
| 2012-09-30 | $29.43M 10-Q · filed 2013-11-12 | $55.11M derived: sum of 2 quarters · filed 2013-11-12 | $84.79M 10-Q · filed 2013-11-12 | $118.48M derived: sum of 4 quarters · filed 2014-03-07 | ||||
| 2012-06-30 | $25.68M 10-Q · filed 2013-08-01 | $55.36M 10-Q · filed 2013-08-01 | $89.05M derived: sum of 3 quarters · filed 2014-03-07 | $115.09M derived: sum of 4 quarters · filed 2014-03-07 | ||||
| 2012-03-31 | $29.68M 10-Q · filed 2013-05-10 | $63.37M derived: sum of 2 quarters · filed 2014-03-07 | $89.41M derived: sum of 3 quarters · filed 2014-03-07 | $115.89M derived: sum of 4 quarters · filed 2014-03-07 | ||||
| 2011-12-31 | $33.69M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-07 | $59.73M derived: sum of 2 quarters · filed 2014-03-07 | $86.21M derived: sum of 3 quarters · filed 2014-03-07 | $115.94M 10-K · filed 2014-03-07 | ||||
| 2011-09-30 | $26.05M 10-Q · filed 2012-11-07 | $52.53M derived: sum of 2 quarters · filed 2012-11-07 | $82.26M 10-Q · filed 2012-11-07 | $105.94M derived: sum of 4 quarters · filed 2013-03-11 | ||||
| 2011-06-30 | $26.48M 10-Q · filed 2012-08-02 | $56.21M 10-Q · filed 2012-08-02 | $79.89M derived: sum of 3 quarters · filed 2013-03-11 | $104.92M derived: sum of 4 quarters · filed 2013-03-11 | ||||
| 2011-03-31 | $29.73M 10-Q · filed 2012-05-03 | $53.41M derived: sum of 2 quarters · filed 2013-03-11 | $78.44M derived: sum of 3 quarters · filed 2013-03-11 | $103.75M derived: sum of 4 quarters · filed 2013-03-11 | ||||
| 2010-12-31 | $23.68M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-11 | $48.71M derived: sum of 2 quarters · filed 2013-03-11 | $74.02M derived: sum of 3 quarters · filed 2013-03-11 | $100.63M 10-K · filed 2013-03-11 | ||||
| 2010-09-30 | $25.03M 10-Q · filed 2011-11-01 | $50.34M derived: sum of 2 quarters · filed 2011-11-01 | $76.95M 10-Q · filed 2011-11-01 | |||||
| 2010-06-30 | $25.31M 10-Q · filed 2011-08-09 | $51.91M 10-Q · filed 2011-08-09 | ||||||
| 2009-12-31 | $100.66M 10-K · filed 2012-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |